Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Sorbent Therapeutics
company
About
Sorbent Therapeutics develops fluid-retaining polymers for kidney disease therapeutics.
- 11 - 50
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $21.80M
- Industries
- Biopharma,Biotechnology,Pharmaceutical
- Founded date
- Jan 1, 2005
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Sorbent Therapeutics, Inc. develops treatment for end stage renal disease patients undergoing dialysis. The company develops fluid retaining polymers for therapeutic uses, such as treatment of kidney diseases. Sorbent Therapeutics, Inc. was founded in 2005 and is based in Vernon Hills, Illinois.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
5
$84.88M
Sorbent Therapeutics has raised a total of
$84.88M
in funding over 2 rounds. Their latest funding was raised on
May 15, 2014 from a Series D round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| May 15, 2014 | Series D | $6.50M | 2 | — | — | Detail |
| Apr 1, 2013 | Series Unknown | $2.53M | 1 | — | — | Detail |
| Aug 8, 2012 | Series C | $18.05M | 1 | — | — | Detail |
| Jun 30, 2011 | Series B | $36M | 2 | — | — | Detail |
| Sep 13, 2010 | Series B | $21.80M | 2 |
AgeChem Venture Fund
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
2
Sorbent Therapeutics is funded by 2 investors.
ARCH Venture Partners
and AgeChem Venture Fund
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
ARCH Venture Partners
|
— | Series D |
|
AgeChem Venture Fund
|
— | Series D |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
